Evolution of functional antibodies following acute Epstein-Barr virus infection

PLoS Pathog. 2022 Sep 6;18(9):e1010738. doi: 10.1371/journal.ppat.1010738. eCollection 2022 Sep.

Abstract

While Epstein-Barr virus causes mostly asymptomatic infection, associated malignancies, and autoimmune and lymphoproliferative diseases occur. To dissect the evolution of humoral immune responses over the course of EBV infection and to gain a better understanding of the potential contribution of antibody (Ab) function to viral control, we comprehensively profiled Ab specificities and Fc-functionalities using systems serology and VirScan. Ab functions against latent (EBNA1), early (p47/54) and two late (gp350/220 and VCA-p18) EBV proteins were overall modest and/or short-lived, differing from humoral responses induced during acute infection by other viruses such as HIV. In the first year post infection, only p18 elicited robust IgM-driven complement deposition and IgG-driven neutrophil phagocytosis while responses against EBNA-1 were largely Fc-functionally silent and only matured during chronic infection to drive phagocytosis. In contrast, Abs against Influenza virus readily mediated broad Fc-activity in all participants. These data suggest that EBV evades the induction of robust Fc-functional Abs, potentially due to the virus' life cycle, switching from lytic to latent stages during infection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Viral
  • Epstein-Barr Virus Infections*
  • Epstein-Barr Virus Nuclear Antigens
  • Herpesvirus 4, Human
  • Humans
  • Immunoglobulin G
  • Immunoglobulin M

Substances

  • Antibodies, Viral
  • Epstein-Barr Virus Nuclear Antigens
  • Immunoglobulin G
  • Immunoglobulin M

Associated data

  • Dryad/10.5061/dryad.7pvmcvdwn